NCT02910063 2021-01-13Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHLAmgenPhase 2/3 Completed41 enrolled 18 charts
NCT00538096 2008-09-05A Phase I Study to Evaluate Safety, Tolerability in Adults With LymphomaMedImmune LLCPhase 1 Withdrawn18 enrolled